Transactions (Tables)

12 Months Ended

Dec. 31, 2019

Schedule of allocation of purchase price

The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2018, as follows (in thousands):



Purchase consideration:
Cash	$	124,652
Fair value of Class B common stock issued	83,173
Fair value of contingent consideration	3,200
Total consideration	$	211,025

Tangible assets acquired:
Cash and cash equivalents	$	5,963
Accounts receivable	5,559
Prepaid expenses and other current assets	7,901
Property and equipment	381
Other noncurrent assets	148

Identifiable intangible assets acquired:
Customer relationships	72,500
Technology	27,000
Corporate trade name	4,300
Provider network contracts	9,600

Liabilities assumed:
Accounts payable	1,167
Accrued liabilities	1,494
Accrued compensation and employee benefits	3,966
Reserve for claims and performance-based arrangements	18,631
Deferred tax liabilities	24,041
Other long-term liabilities	6,138

Goodwill	133,110
Net assets acquired	$	211,025

Schedule of net assets acquired

The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 2, 2018, as follows (in thousands):



Purchase consideration
Cash paid to NMHC	$	10,000
Cash paid to escrow agent	252
Total consideration	$	10,252

Identifiable intangible assets acquired and liabilities assumed
Customer relationships	$	2,700
Provider network contracts	2,300
Above market lease	(100		)
Accrued compensation and employee benefits	(474		)

Goodwill	5,826
Net assets acquired	$	10,252

Business acquisition, pro forma information

The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company’s historical financial information on a pro forma basis (in thousands, except per share data).



	For the Years Ended December 31,
	2018			2017
Total revenue	$	763,624		$	679,323
Net loss	(69,337		)	(80,990		)
Net loss attributable to non-controlling interests	(3,554		)	(11,544		)
Net loss attributable to common shareholders of Evolent Health, Inc.	(65,783		)	(69,446		)

Loss per common share
Basic and diluted	$	(0.85	)	$	(1.08	)